SPRO Spero Therapeutics

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday August 5th, 2024 at 4:30 p.m. ET to report financial results for second quarter 2024 and provide an update on its business and pipeline.

To access the call, please dial 1-877-269-7751 (domestic) or 1-201-389-0908 (international) and refer to conference ID 13747505, or click on this and request a return call. The audio webcast can be accessed live on this and also on the “Investor Relations” page of the Spero Corporate Website at . The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics

Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a multi-asset, clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections. For more information - 

Investor Relations Contact:

Shai Biran, PhD

Spero Therapeutics

Media Inquiries:



EN
29/07/2024

Underlying

SPROSpero Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Spero Therapeutics

 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposu...

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy Phase 1 study showed significant lung uptake and enhanced epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations of SPR719 (active moiety of SPR720) CAMBRIDGE, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced the publication...

October 2, 2024 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics to Present at Upcoming September Investor Conferenc...

Spero Therapeutics to Present at Upcoming September Investor Conferences CAMBRIDGE, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 26th Annual Global Inves...

September 4, 2024 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Announces Second Quarter 2024 Operating Results and...

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update Enrollment concluded in the Phase 2a proof-of-concept clinical trial evaluating SPR720 in nontuberculous mycobacterial pulmonary disease (NTM-PD); preliminary data expected in 4Q 2024New SPR720 in-vitro resistance data to be presented at IDWeek 2024 conference in OctoberCompany announces departure of Chief Medical Officer Kamal Hamed, MD, MPH, MBA; Appoints Board member and Chair of Development Committee John C. Pottage, Jr., M.D., as Special Advisor to oversee medical function; search ongoing ...

August 5, 2024 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics to Report Second Quarter 2024 Financial Results and...

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024 CAMBRIDGE, Mass., July 29, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that management will host a conference call and live audio webcast on Monday August 5th, 2024 at 4:30 p.m. ET to report financial results for second quarter 2024 and provide an update...

July 29, 2024 1 EN
 PRESS RELEASE
Free
SPRO Spero Therapeut...

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rul...

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMBRIDGE, Mass., July 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on May 28, 2024, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 227,500 restricted stock unit awards (RSUs) to new employees under the Spero Therapeutics, Inc. 2019 Ind...

July 3, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch